Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Attenuon is a clinical-stage pharmaceutical company seeking to develop a new generation of cancer therapeutics.
Instead of being toxic to cells, these therapies are designed to selectively disrupt cellular signalling processes important
to tumour growth and metastasis. Based on this approach, Attenuon hopes to develop therapies that will be effective
against many types of cancer, produce few side effects, be less prone to acquired drug resistance, be suitable for longterm
use, and work well with existing therapies.